Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2026
Resmed reported Q3 revenue of $1.4 billion, up 11% year-over-year, with non-GAAP EPS rising 21% to $2.86 driven by 290 basis points of gross margin expansion. Operating cash flow was $554 million, supporting $262 million in capital returns via $175 million of share repurchases and $87 million in dividends.
Key figures
- Eps
- 2.74
- Revenue
- $1.4 billion
- Revenue Yoy
- 11%
- Non gaap eps
- 2.86
- Dividend per share
- 0.6
- Shares repurchased
- 673000
- Operating cash flow
- 554000000
- Gross margin expansion bps
- 290
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.